[{"data":1,"prerenderedAt":157},["ShallowReactive",2],{"article-525":3},{"id":4,"title":5,"articleType":6,"sourceType":7,"sourceKey":8,"securityCode":9,"exchange":10,"exchangeName":11,"createdAt":12,"paragraphs":13,"referenceList":21},525,"西奥罗尼冲击“癌王”胰腺癌：三重机制亮眼，但市场突围仍需跨过三道坎","analysis","bulletin","sse_bulletin:11626","688321","sse","上交所",1767860232,[14,15,16,17,18,19,20],"胰腺癌被称为“癌中之王”，晚期患者中位总生存期（mOS）长期徘徊在不足1年的水平，是全球公认的最难治癌症之一。就在2026年1月8日，微芯生物（688321）发布公告称，其原创新药西奥罗尼胶囊联合PD-1单抗（特瑞普利单抗）及标准化疗（AG方案），获国家药监局批准开展一线治疗转移性胰腺导管腺癌的临床研究。这一消息点燃市场对突破“生存期天花板”的期待，但冷静审视公告细节与行业格局，真正的挑战或许才刚刚开始。","西奥罗尼的核心竞争力在于其“三通路、三重打击”的独特机制。根据公司公告，该药可同时抑制Aurora B、VEGFR/PDGFR/c-Kit和CSF1R/DDR1三大靶点。通俗理解，这相当于一支特种部队执行三项任务：一是精准斩首（抑制Aurora B，直接阻断肿瘤细胞分裂）；二是切断补给线（抑制VEGFR/PDGFR，破坏肿瘤血管生成）；三是瓦解敌方防御工事（调控CSF1R/DDR1，打破免疫抑制微环境，让免疫细胞能有效攻击癌细胞）。这种多靶点协同策略，理论上能克服胰腺癌致密基质和免疫荒漠的天然屏障。","前期II期临床数据确实令人鼓舞。据微芯生物披露，在西奥罗尼联合AG方案（白蛋白紫杉醇+吉西他滨）的II期研究中，6个月无进展生存率（PFS率）接近80%。作为对比，历史数据显示，单纯AG方案的6个月无进展生存率在现有文献中未明确给出具体数值范围，但其疗效已被多项研究证实具有临床意义。这意味着疾病控制时间可能显著延长。然而，公告并未披露具体的中位PFS（mPFS）数值及其95%置信区间，这使得我们无法进行更精确的疗效评估，也留下了第一个关键疑问。","更大的想象空间在于本次获批的III期方案——联合PD-1单抗。这标志着微芯生物正试图复制“化疗+靶向+免疫”的成功范式。但随之而来的是三重现实挑战。首先，是高昂的治疗费用。尽管部分PD-1单抗如帕博利珠单抗已纳入医保，但西奥罗尼作为尚未上市的1类新药，其联合用药的总成本仍存在不确定性，且可能因新药定价与医保谈判结果而显著上升。对于一个年新发约13万例、多数患者确诊即晚期的病种，支付能力是决定市场天花板的关键。其次，是医保准入的不确定性。尽管2025年新版医保目录纳入了部分胰腺癌新药，但西奥罗尼作为尚未上市的1类新药，其定价与谈判结果仍是未知数。若无法进入医保，其市场渗透将受到极大限制。","最严峻的挑战，来自赛道上汹涌而来的竞争者——KRAS G12D抑制剂。超过90%的胰腺癌存在KRAS突变，其中G12D亚型占比近50%。目前，Revolution Medicines的RMC-9805、Mirati Therapeutics的MRTX1133以及加科思药业的JAB-23E73等泛KRAS抑制剂已进入临床研究阶段。特别是Revolution Medicines的泛KRAS抑制剂daraxonrasib（RMC-6236），在II期试验中针对胰腺癌的客观缓解率已达20%，中位无进展生存期（PFS）达8.1个月，并已获得FDA突破性疗法认定。这些“精准制导”药物的进展，为胰腺癌治疗带来新希望，但其与西奥罗尼这类多靶点药物之间的市场关系尚不明确，有资料显示现有资料无法支持“直接挤压市场空间”的结论。","此外，公告虽提及西奥罗尼能“改善抑制性肿瘤微环境”，但并未明确说明是否已获得组织学或影像学的直接证据支持。同时，微芯生物与君实生物（Junshi Biosciences）是否就特瑞普利单抗的联用签署了正式合作协议，也未在公告中披露，这为后续临床推进带来一丝合作层面的不确定性。","总而言之，西奥罗尼凭借其独特的三重机制，在胰腺癌这片“死亡之地”上开辟了一条充满希望的新路径。II期数据展现出的潜力值得肯定，但投资者必须清醒认识到，从临床数据到商业成功，中间横亘着支付能力、医保谈判和激烈竞争三座大山。这场攻坚战，才刚刚进入最关键的阶段。",[22,27,32,37,41,45,50,54,58,62,66,70,75,79,84,89,93,97,101,105,109,113,117,121,125,129,133,137,142,146,149,153],{"index":23,"title":24,"sourceName":25,"url":26},0,"自愿披露关于西奥罗尼胶囊获得药物临床试验批准通知书的公告","上海证券交易所","https://www.sse.com.cn/disclosure/listedinfo/announcement/c/new/2026-01-09/688321_20260109_0U2C.pdf",{"index":28,"title":29,"sourceName":30,"url":31},1,"微芯生物：自愿披露关于西奥罗尼胶囊一线治疗广泛期小细胞肺癌获得药物临床试验批准通知书的公告","新浪","https://vip.stock.finance.sina.com.cn/corp/view/vCB_AllBulletinDetail.php?id=10574453",{"index":33,"title":34,"sourceName":35,"url":36},2,"微芯生物: 自愿披露关于西奥罗尼胶囊一线治疗广泛期小细胞肺癌获得药物临床试验批准通知书的公告","","https://4g.stockstar.com/detail/SN2024110100052026",{"index":38,"title":39,"sourceName":35,"url":40},3,"微芯生物：西奥罗尼胶囊获临床试验批准","https://www.nbd.com.cn/articles/2026-01-08/4212177.html",{"index":42,"title":43,"sourceName":35,"url":44},4,"胰腺癌的靶向治疗进展及前沿","https://manu41.magtech.com.cn/Jweb_clyl/CN/10.12092/j.issn.1009-2501.2025.02.004",{"index":46,"title":47,"sourceName":48,"url":49},5,"重大利好！胰腺癌、肺癌等用药，纳入医保→","澎湃新闻","https://www.thepaper.cn/newsDetail_forward_32125834",{"index":51,"title":52,"sourceName":30,"url":53},6,"医药行业周报：KARS抑制剂：肿瘤治疗的蓝海赛道","https://stock.finance.sina.com.cn/stock/go.php/vReport_Show/kind/lastest/rptid/821061952590/index.phtml",{"index":55,"title":56,"sourceName":35,"url":57},7,"Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway","https://link.springer.com/article/10.1007/s12032-025-02683-8",{"index":59,"title":60,"sourceName":35,"url":61},8,"2025年中国胰腺癌药物行业发展现状、竞争格局与展望「图」","https://www.huaon.com/channel/trend/1047834.html",{"index":63,"title":64,"sourceName":35,"url":65},9,"胰腺癌治疗费用解析,胰腺癌医保报销政策","https://www.ay91.com/18796.html",{"index":67,"title":68,"sourceName":35,"url":69},10,"Triple meeting 2024 – Revolution shows selective KRAS promise","https://www.oncologypipeline.com/apexonco/triple-meeting-2024-revolution-shows-selective-kras-promise",{"index":71,"title":72,"sourceName":73,"url":74},11,"西奥罗尼","百度","https://baike.baidu.com/item/%E8%A5%BF%E5%A5%A5%E7%BD%97%E5%B0%BC/61282945",{"index":76,"title":77,"sourceName":35,"url":78},12,"胰腺癌靶向治疗及免疫治疗的研究新进展","https://cjournal.hep.com.cn/1007-9572/CN/1189606022516892597",{"index":80,"title":81,"sourceName":82,"url":83},13,"微芯生物:自愿披露关于西奥罗尼胶囊治疗转移性胰腺导管腺癌临床试验申请获得受理的公告","东方财富","https://guba.eastmoney.com/news,688321,1621279757.html",{"index":85,"title":86,"sourceName":87,"url":88},14,"微芯生物西奥罗尼胶囊治疗胰腺癌II期临床试验申请获得批准","网易","https://www.163.com/dy/article/J4TRHI3S0519DFFO.html",{"index":90,"title":91,"sourceName":35,"url":92},15,"Combination strategy offers hope for durable responses in pancreatic cancer","https://www.nature.com/articles/d42473-023-00039-2",{"index":94,"title":95,"sourceName":35,"url":96},16,"2025医保药品目录公布：胰腺癌等药物填补空白 百万元的CAR-T首进商保创新药目录","https://static.cdsb.com/micropub/Articles/202512/91fc98310eec4f4599e1038d48ac3b46.html",{"index":98,"title":99,"sourceName":30,"url":100},17,"微芯生物：关于西奥罗尼单药治疗三线及以上小细胞肺癌III期临床试验结果的公告","https://vip.stock.finance.sina.com.cn/corp/view/vCB_AllBulletinDetail.php?id=10633366",{"index":102,"title":103,"sourceName":35,"url":104},18,"Unveiling New KRAS\u003Csup>G12D\u003C/sup>Inhibitors: A Promising Approach for Pancreatic Cancer Therapy","https://pmc.ncbi.nlm.nih.gov/articles/PMC10350939/",{"index":106,"title":107,"sourceName":35,"url":108},19,"Combining immunotherapy with KRAS inhibitor eliminates advanced KRAS-mutant pancreatic cancer in preclinical models","https://www.mdanderson.org/newsroom/combining-immunotherapy-kras-inhibitor-eliminates-advanced-kras-mutant-pancreatic-cancer-preclinical-models.h00-159621012.html",{"index":110,"title":111,"sourceName":35,"url":112},20,"Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer?","https://www.cancer.gov/news-events/cancer-currents-blog/2024/pancreatic-cancer-kras-inhibitors-chemotherapy",{"index":114,"title":115,"sourceName":35,"url":116},21,"Combination of RAS inhibition and immunotherapy provides breakthrough for pancreatic cancer","https://www.news-medical.net/news/20250314/Combination-of-RAS-inhibition-and-immunotherapy-provides-breakthrough-for-pancreatic-cancer.aspx",{"index":118,"title":119,"sourceName":35,"url":120},22,"Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations","https://www.globenewswire.com/news-release/2025/06/23/3103444/0/en/Revolution-Medicines-Announces-FDA-Breakthrough-Therapy-Designation-for-Daraxonrasib-in-Previously-Treated-Metastatic-Pancreatic-Cancer-with-KRAS-G12-Mutations.html",{"index":122,"title":123,"sourceName":35,"url":124},23,"KRAS Inhibitors in Pancreatic Cancer: Hope on the Horizon?","https://www.mdedge.com/fedprac/avaho/article/270703/gastrointestinal-cancer/kras-inhibitors-pancreatic-cancer-hope-horizon",{"index":126,"title":127,"sourceName":35,"url":128},24,"一针少花两千，新版医保目录调整能省多少钱","https://health.gmw.cn/2026-01/08/content_38525494.htm",{"index":130,"title":131,"sourceName":35,"url":132},25,"胰腺癌化疗药物有哪些进医保的","https://zl.youlai.cn/zl/article/134624.html",{"index":134,"title":135,"sourceName":35,"url":136},26,"MSK Discovery Suggests Opportunity to Improve Effectiveness of KRAS Inhibitors Against Pancreatic Cancer","https://www.mskcc.org/news/msk-discovery-suggests-opportunity-to-improve-effectiveness-of-kras-inhibitors-against-pancreatic",{"index":138,"title":139,"sourceName":140,"url":141},27,"微芯生物分享西奥罗尼II期临床阶段数据","搜狐","https://www.sohu.com/a/925572206_120988576",{"index":143,"title":144,"sourceName":87,"url":145},28,"重磅综述！胰腺癌精准诊疗全景图：从分子发病机制到新兴治疗策略|肿瘤|癌变|胰脏癌|癌症患者_网易订阅","https://www.163.com/dy/article/KIELS1260534TMVS.html",{"index":147,"title":47,"sourceName":140,"url":148},29,"https://www.sohu.com/a/962698512_354682",{"index":150,"title":151,"sourceName":140,"url":152},30,"一桩超20亿美元BD狙向‘癌王’，搅动泛KRAS赛道格局","https://www.sohu.com/a/968309506_397362",{"index":154,"title":155,"sourceName":35,"url":156},31,"What is the cost of treating pancreatic cancer?","https://www.buoyhealth.com/cost/cost-to-treat-pancreatic-cancer",1767860939179]